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ARTICLE
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Abstract
Acute coronary syndromes (ACS) may complicate the clinical course of patients with Coronavirus Disease 2019
(COVID-19). It is still unclear whether this condition is a direct consequence of the primary disease. However, several
mechanisms including direct cellular damage, endothelial dysfunction, in-situ thrombosis, systemic inﬂammatory
response, and oxygen supply-demand imbalance have been described in patients with COVID-19. The onset of a prothrombotic state may also be facilitated by the endothelial dysfunction secondary to the systemic inﬂammatory response
and to the direct viral cell damage. Moreover, dysfunctional endothelial cells may enhance vasospasm and platelet
aggregation.
The combination of these factors promotes atherosclerotic plaque instability, thrombosis and, consequently, type 1
myocardial infarction.
Furthermore, severe hypoxia due to extensive pulmonary involvement, in association with other conditions described
in COVID-19 such as sepsis, tachyarrhythmias, anemia, hypotension, and shock, may lead to mismatch between oxygen
supply and demand, and cause type 2 myocardial infarction.
A deeper understanding of the potential pathophysiological mechanisms underlying ACS in patients with COVID-19
could help the therapeutic management of these very high-risk patients.
Keywords: Acute coronary syndromes, Myocardial infarction, Coronary artery disease, Novel coronavirus 2019,
COVID-19, SARS-CoV-2, Endothelial dysfunction, Oxidative stress

1. Introduction
fter the detection of the ﬁrst cases in Hubei
Province, China, Coronavirus Disease 2019
(COVID-19) spread rapidly worldwide and reached
pandemic proportions [1,2].
Although mainly involving the respiratory apparatus, COVID-19 can assume the characteristics of a
multi-systemic disease involving many organs and
lead to death in 15% of hospitalized patients [3].

A

Among these systemic effects, cardiovascular
involvement is frequently reported and impact
negatively on patient clinical outcome [4e13].
Although a clear association between these two
conditions has not yet been found, a signiﬁcant
proportion of patients with COVID-19 may be
complicated by acute coronary syndromes (ACS)
[14,15], this aspect must be hardly considered, since
cardiovascular risk factors are widely represented in
COVID-19 patients. As reported in other infectious
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diseases, COVID-19 may promote atherosclerotic
plaque instability resulting in rupture, thrombus
formation and type 1 myocardial infarction (MI)
[16,17]. However, in the context of a systemic disease, other factors may contribute to the ACS
pathophysiology including cellular damage mediated by the virus or systemic inﬂammatory
response, microvascular thrombosis, endothelial
dysfunction and the mismatch between oxygen demand and availability secondary to respiratory
involvement [18e22].
The aim of this review is to describe the potential
pathophysiological pathways of ACS in COVID-19
patients, focusing on the translational application
and on possible therapeutic perspectives.

2. Pathogenesis and transmission of COVID-19
COVID-19 is caused by severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) [23]. The
internalization of the virus in the target host cells is
mediated by the interaction between the angiotensin converting enzyme 2 (ACE2) receptor
expressed by the cells, and the spike (S) protein
expressed by the virus [24,25]. In this context,
interferon release enhances the expression of
further ACE2 receptors on the membranes of
nearby pneumocytes and promotes the inﬂammatory response and the development of interstitial
edema, microvascular thrombosis, and alveolar
damage, which combined can precipitate the onset
of an acute respiratory distress syndrome (ARDS)
[26]. Viral transmission occurs through close individual contact and is mediated by respiratory
droplets and subsequent inhalation of viral particles
[27]. After an average incubation of approximately
ﬁve days, the early clinical presentations of the
disease are similar to other viral respiratory syndromes, including fever, cough, shortness of breath,
fatigue, myalgias, headache, and gastrointestinal
involvement [1]. The subsequent progression can be
extremely wide, varying from asymptomatic or
minimally symptomatic to life-threatening or fatal
conditions, characterized by systemic inﬂammatory
response syndrome, ARDS, multiple organ failure,
and death [4,15,28].

3. The epidemiology paradox of ACS in
COVID-19
Although ACS can complicate the clinical course
of patients infected by SARS-CoV-2, a dramatic
reduction in hospital admissions for ACS was
observed during the ﬁrst phase of the pandemic as
demonstrated by the number of urgent or emergent

coronary angiography performed [29e33]. Zhang
et al. in a study involving 395 STEMI patients reported a halving of the number of primary percutaneous coronary interventions (pPCI) in 2020
compared to 2019 and 2018, and a concomitant increase in the use of ﬁbrinolysis [34]. De Luca et al.
also reported a signiﬁcant reduction of pPCI performed in March and April 2020 compared with the
same period of 2019 [35]. As expected, longer
ischemia and door-to-balloon times were reported
[36]. In contrast, ﬁbrinolysis was frequently
preferred as reperfusion strategy in patients with
STEMI and COVID-19 [34,37e39].
This change in the rate of hospital admissions for
ACS could have several explanations. Surely the
governmental restrictive measures such as national
lockdowns and the media emphasis on the rapid
spread of the pandemic could have played a critical
role in making the population more hesitant on
seeking medical attention and into underestimating
potentially life-threatening conditions. Moreover,
the reorganization of health services and pathways
has impacted on the efﬁciency of the emergency
system, especially for time-dependent diseases such
as STEMI [40]. This could also explain the signiﬁcant
increase in the incidence of out-of-hospital cardiac
arrest, the most dreadful complication of ACS,
which has been widely described in this period
[35,41,42].
In addition, in the context of hospital access ﬂows,
it should be considered a substantial reduction in all
cause access to the emergency cardiology department, which was more profound when COVID-19
cases increased and less evident during periods in
which the epidemic curve tended to ﬂatten [43].

4. Mechanisms of acute coronary syndromes in
COVID-19
The characteristics of ACS in patients with
COVID-19, such as angiographic evidence of unobstructed coronary arteries, stent thrombosis,
multiple thrombotic culprit lesions, and high
thrombus burden, suggest distinct pathophysiological pathways [37,44,45]. (Fig. 1). MI may be also the
ﬁrst presentation of SARS-CoV-2 infection and may
not correlate with the severity of lung involvement
[44,46].
4.1. Hemostatic abnormalities
In hospitalized patients with COVID-19, multiple
hemostatic abnormalities have been described and
may be related to poorer clinical outcome. The most
representative were decreased platelet counts,
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Fig. 1. Pathophysiology of ACS in COVID-19. SARS-CoV-2, through
ACE2 receptors, enters inside pneumocytes, macrophages, and endothelial cells. Hypoxia secondary to serious pulmonary involvement,
which may escalate into ARDS, may cause type 2 MI due to oxygen
supply-demand imbalance. Moreover, the excessive inﬂammatory
response related to infection promotes the release of cytokines such as
IL-1, IL-6, IL-7, TNFa, and IFNg. The cytokine storm can facilitate the
onset of endothelial dysfunction with subsequent production of oxidative
and prothrombotic factors. Furthermore, the virus can directly damage
the endothelium by interacting with its cells. Lastly, the state of
hyperinﬂammation increases the activity of the sympathetic nervous
system favoring coronary vasospasm. This context may then enhance
atheromatous plaque rupture and platelet aggregation resulting in
thrombosis and type 1 MI. ACS, acute coronary syndrome; ACE2,
Angiotensin Converting Enzyme 2; COVID-19, Coronavirus Disease
2019; IFNg, Interferon g; IL-1, Interleukin 1; IL-6, Interleukin 6; IL-7,
Interleukin 7; MI, myocardial infarction; SARS-CoV-2, Severe Acute
Respiratory Syndrome Coronavirus 2; TNFa, Tumor Necrosis Factor a.

raised d-dimer serum levels, and prolonged prothrombin time [47,48]. Huang et al., in an observational study on hospitalized patients with COVID19, reported that patients with higher levels of ddimer were more likely to need intensive cares [49].
A study by Tang et al. also reported increased levels
of d-dimer and ﬁbrinogen degradation products,
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and a slight prolongation of the prothrombin time in
patients hospitalized or who died due to severe
forms of COVID-19 [50]. Whether these disorders
are directly associated to the activity of the virus or
are a consequence of an excessive inﬂammatory
response secondary to the infection is yet to be
deﬁned [51]. By comparing laboratory blood samples obtained from patients with ARDS due to other
causes and patients with ARDS due to SARS-CoV-2,
patients with COVID-19 showed a signiﬁcant increase in procoagulant and acute phase factors
suggesting that the cytokine storm (CS) observed in
these patients may act as a primary trigger in the
development of thrombotic complications [52]. The
systemic inﬂammatory response, through cytokines
activity, may facilitate the expression of ultralarge
von Willebrand factor multimers (ULVWF) and tissue factor (TF), which take part at various stages in
the hemostatic mechanisms, enhancing thrombin
production and the development of a procoagulant
state [50,53e55]. A potential contributing factor to
the development of SARS-CoV-2-related coagulopathy might be the presence of lupus anticoagulant
(LA) [53], a condition that typically occurs in inﬂammatory and infectious disorders where cellular
injury may expose phospholipid moieties, that are
not usually reachable by the immune system, with
consequent activation of the coagulation cascade
and thrombus formation [56].
The presence of this procoagulant environment
could explain the frequent occurrence of thrombotic
complications such as venous thromboembolism
(VTE), pulmonary embolism (PE), and ACS in patients with COVID-19 [7,18,22,44]. Furthermore, this
patient population seem to have a peculiar phenotype in the development of ACS. Choudry et al., in a
cohort of STEMI patients with COVID-19, reported
an increased incidence of multiple thrombotic lesions, a higher thrombotic burden, and less successful PCI as assessed by the myocardial blush
grade (a marker of myocardial perfusion) after pPCI,
compared with a control group of SARS-CoV-2
negative STEMI patients [45,57,58]. In addition,
Rodriguez-Leor et al. reported a high incidence of
stent thrombosis (4.1%) during the hospitalization in
patients with COVID-19 and STEMI [30], an event
described in less than 1% in the general STEMI
population up to 1 year from the index event
[59e63].
4.2. Endothelial dysfunction
Vascular endothelium plays a crucial role in
regulating the interaction between the circulatory
system and tissues, and it is the main responsible
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for preserving vascular homeostasis by regulating
vasomotility, immune response, platelet aggregation, coagulation, and vascular permeability. Endothelium can be harmed by several mechanisms,
including oxidative stress due to an intracellular
increase of superoxide anions, a condition already
described in several conditions such as diabetes,
hypertension, elderly age, and smoking. Hence, a
dysfunctional endothelium will assume a predominantly vasoconstrictive and procoagulant state,
promoting the development of ACS [64,65].
Endothelial dysfunction is also a key player in the
pathophysiology of COVID-19 complications
[66,67]. The endothelium can be impaired either
directly by the virus or by the inﬂammatory
response secondary to the infection, leading to
venous, arterial, and microvascular thrombosis
[21,68]. The endothelium increases the expression
and release of TF, von Willebrand factor (vWf),
thromboxane and plasminogen activator inhibitor-1
(PAI-1) [69e71] Furthermore, the CS favors the
production of superoxide anions with consequent
increase in oxidative stress and endothelial damage,
creating a vicious loop that can lead to severe
vascular complications [72e74]. An increased production and release of endothelin-1 also occurs in
these circumstances, with consequent increased
vasoconstriction and platelet aggregation [75].
These conditions could be exacerbated in patients
with preexisting CV risk factors and CAD, favoring
the precipitation toward an ACS or other thrombotic
complications.
The role of the endothelium in the development of
vascular complications encourages future investigations on endothelium-targeting therapy,
including ACE inhibitors (ACEi) and statins [76e79].
4.3. Inﬂammatory response and cytokine storm
Inﬂammation is a leading mechanism in the
development and progression of atherosclerosis
[80]. During the acute phase of a viral infection, the
CS can impair the physiological homeostasis by
activating platelets, directly damaging the endothelium, and stimulating vasoconstriction by
increasing sympathetic activity, facilitating the
development of a pro-thrombotic state [16,81]. The
interaction between these biological and mechanical
agents can disrupt the atheromatous plaque architecture, facilitating the formation of thrombus and
the occurrence of acute coronary syndrome [82,83].
An aberrant inﬂammatory response is typically
associated with severe forms of COVID-19 [49,51].
Due to its self-expressing ability, interleukin-1 (IL-1)
is the leading facilitator of CS, promoting the

development of a self-enhancing inﬂammatory
response [84]. The release of further inﬂammatory
molecules, such as tumor necrosis factor (TNFa),
interleukin-6 (IL-6), and various chemoattractant
molecules, which facilitate tissue penetration of inﬂammatory cells is also promoted by IL-1 [85e87].
IL-6 further promotes the production of acute phase
reactants, such as ﬁbrinogen and plasminogen
activator inhibitor-1 (PAI-1) priming a prothrombotic and antiﬁbrinolytic state. Many studies
have consistently reported increased levels of
proinﬂammatory factors, such as IL-1, IL-6, IL-10,
IFNg, granulocyte colony-stimulating factor (GCSF), monocyte chemoattractant protein (MCP1),
macrophage inﬂammatory protein 1 alpha (MIP1A),
platelet-derived growth factor (PDGF), TNFa, and
vascular endothelial growth factor (VEGF) in patients with COVID-19, suggesting the possibility of
SARS-CoV-2-induced CS [49,88]. Cytokines impair
the endothelial function and contribute to the
development of thrombotic complications [50,53,89].
This evidence emphasizes the potential usefulness
of an individualized therapy targeting these factors
[90].
4.4. Oxygen supply/demand imbalance
Approximately 60% of patients with COVID-19
die due to hypoxemic respiratory failure [91]. The
hypoxic state, in association with other disorders
that may occur in critical COVID-19 patient,
including sepsis, tachyarrhythmias, anemia, hypotension, and shock, may facilitate the onset of type 2
MI as a consequence of an imbalance between oxygen supply and demand [6,92]. The characteristics
of these patients that are frequently elderly and with
multiple comorbidities, justify the a poorer prognosis compared to patients with type 1 MI [93]. the
comorbidities and frailty increase the risk of type 2
MI, a and contribute to the high mortality rate of
these patients [4].

5. Myocardial infarction with non-obstructive
coronary arteries
Non-obstructed coronary arteries have been
widely reported in COVID-19 patients suffering an
ACS, with a prevalence ranging from 30% to 40%
[30,44,46,94] Different mechanisms may be responsible for the pathogenesis of myocardial infarction
with non-obstructed coronary arteries (MINOCA),
including plaque erosion, microthrombus formation, and coronary vasospasm [44,95,96]. In the
context of COVID-19, the mechanisms of MINOCA
are probably under-investigated due to difﬁculties
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of performing invasive and noninvasive tests that
are time consuming and increase the exposure of
the operator to the risk of contagion [97e102].
However, CS seems to be a key player also in
MINOCA due to its potential to impair the endothelial integrity and function [103,104].
Takotsubo syndrome (TTS) is a particular condition that mimics ACS [105] clinical presentation and
has been reported in 2e4% of hospitalized patients
with COVID-19 [15,106e108]. This disease could
also lead to severe complications and dramatically
impact on the survival of these patients [109e113].
TTS could either be part of the pathophysiological
manifestations of COVID-19 or related to the
physical and emotional stress characterizing SARSCoV-2 infection, leading to increased catecholamine
levels [114]. Also, the psychological stress associated
with COVID-19 spread may have contributed to the
occurrence of TTS and justify the high incidence of
TTS reported during the pandemic period [115,116].

6. Therapeutic perspectives
The need to limit the exposure of health workers
to the risk of contagion has been a major limitation
for the management of SARS-CoV-2 positive STEMI
patients, particularly during the ﬁrst peak of the
pandemic. Scientiﬁc societies have suggested the
use of ﬁbrinolysis as primary treatment [117e119];
however, the increased risk of complications due to
the delay to myocardial reperfusion does not seem
to support this approach over pPCI, which has long
been considered the standard of care [36,45,120,121].
On the other hand, in patients with non-STE and/
or equivocal ECG presentation, a rapid bedside
echocardiogram showing regional wall motion abnormalities play an important role in detecting acute
coronary syndromes early and triaging patients for
invasive or conservative strategies [5].
Antiplatelet agents may have a particular value in
the context of the thrombo-inﬂammatory syndrome
frequently associated with COVID-19. Activated
platelets may release several inﬂammatory mediators that may contribute to CS and [122], by interplaying with inﬂammatory cells, may further
promote endothelial damage and subsequent
thrombus formation [123,124]. Therefore, these
therapeutic regimens could have pleiotropic effects
in this particular STEMI population.
Anticoagulant drugs may also be particularly
useful in COVID-19, since they may exert several
anti-inﬂammatory effects. Unfractionated heparin
(UFH) and low-molecular-weight heparin (LMWH)
can affect the interaction between platelets and
neutrophils and decrease the release of
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inﬂammatory mediators, such as IL-1b, IL-6, Eselectin, and ICAM-1 [125e127] In addition, heparins also possess direct antiviral effects, including
interaction with heparan sulfate, a common
component of many viruses essential for interactions with human host cells [128e130], and the
ability to induce structural changes in the S1 subunit
of SARS-CoV2, preventing virus access into the
target cells [128].
However, it is still unclear what is the best anticoagulant molecule and its dosage [131,132]. A
recent observational study of 4389 patients demonstrated that those receiving anticoagulant treatment
had a lower mortality rate, with no difference between prophylactic and therapeutic dosing [133].
Randomized clinical trials are needed to deﬁne the
best strategy for these patients, and the choice of
antiplatelet/anticoagulant regimens should be individualized for every speciﬁc patient, taking into account his ischemic and hemorrhagic risk [134e137].
Table 1 summarizes the main ongoing trials testing
antithrombotic and/or anticoagulant therapeutic
regimens in patients with COVID-19.
Since endothelial dysfunction plays a prominent
role in the development of ACS in the patient with
COVID-19, ACEi and statins have been hypothesized to prevent the risk of ischemic complication
[77,79].
The ACE2 receptor, used by SARS-CoV-2 to enter
into the host cell, is not inhibited by ACEi and may
have multiple beneﬁcial effects [138]. These mechanisms are accomplished through several pathways
leading to the production of the molecule Angiotensin 1-7 which exert multiple anti-inﬂammatory,
antioxidant, vasodilator, and natriuretic effects [139].
SARS-CoV-2, by binding to ACE2 may interfere
with these effects, causing its cleavage from the
plasma membrane [140]. Conversely, ACEi may
facilitate the overexpression of ACE2 by enhancing
the transcription of its mRNA, leading to the
extrinsicity of its beneﬁcial effects [141]. Based on
this evidence, the use of these medications might
provide a viable preventive strategy in patients with
COVID-19 at risk of developing ACS.
Statins are widely used in posteMI patients [142]
and have shown to be also effective in regulating the
inﬂammatory response at different stages of
COVID-9 due to their ability to interfere with the
Ras, Rho, and Rac GTPases and leading to a
reduction in the expression of various transcription
factors like NF-kВ [143,144]. They may also enhance
nitric oxide production by promoting the expression
of eNOS with an overall antioxidant effect that restores normal endothelial homeostasis [145] At
platelet level, statins were shown to reduce platelet

NCT04445623

NCT04365309

NCT04324463

NCT04333407

CTRI/2020/07/026791

NCT04409834

PARTISAN

PEAC

ACT-COVID19

C-19-ACS

RESIST

COVID-PACT

ICU
patients

Non-ICU
patients

Non-ICU
patients

Non-ICU
patients
Non-ICU
patients
Non-ICU
patients

Population

UFH iv
Enoxaparin 1 mg/kg
Clopidogrel 75 mg
UFH sc
Enoxaparin
40 mg/0.4 mL

Aspirin 75 mg
Clopidogrel 75 mg
Rivaroxaban 2.5 mg
Atorvastatin 40 mg
Omeprazole 20 mg
Aspirin 75 mg
Atorvastatin 40 mg

Aspirin
Rivaroxaban
Colchicine

Aspirin 100 mg

Prasugrel 10 mg

Treatments

Randomized,
open label,
factorial

Randomized,
open label

Randomized,
open label

Randomized,
double blind
Randomized,
open label
Randomized,
open label,
factorial

Design

750

800

3170

4000

128

128

Estimated
enrollement
(n)

Clinical deterioration expressed as
progression of WHO clinical
improvement ordinal score 6
Hierarchical composite: death due to
venous or arterial thrombosis,
pulmonary embolism, clinically
evident DVT, type 1 MI, ischemic
stroke, systemic embolism, or acute
limb ischemia or clinically silent DVT

Clinical recovery time
The time of SARS-CoV2 overcasting
Colchicine vs. control; Aspirin and
Rivaroxaban vs. control:
- composite of invasive mechanical
ventilation or death
- disease progression of 2 points
on a 7-points scale
Aspirin and Rivaroxaban vs. control:
- composite of MACE (MI, stroke,
acute limb ischemia, VTE, death).
All-cause mortality

P/F ratio

Primary endopoint

28

10

30

14
37
45

7

Time of
FU (days)

COVID-19, Coronavirus Disease 2019; DVT, Deep Vein Thrombosis; ECMO, Extra Corporeal Membrane Oxygenation; ICU, Intensive Care Unit; MACE, Major Adverse Cardiovascular Events; MI, Myocardial Infarction; P/F, PaO2/FiO2; RRT, Renal Replacement Therapy; SARS-CoV2, Severe Acute Respiratory Syndrome Coronavirus 2; UFH, Unfractionated
Heparin; VTE, Venous Thromboembolism.

Registration
number

Study name

Table 1. Ongoing randomized clinical trials investigating antithrombotic regimens in patients with COVID-19.
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reactivity and the releasing of proaggregative molecules like thromboxane, isoprostane and TF
[146,147]. Similarly to ACEi, statins may also promote the expression of the ACE2 receptor [148].
Recent observational studies have reported that
hospitalized patients with COVID-19 treated with
statins showed a signiﬁcantly lower mortality than
patients not taking these medications [149,150].
However, their potential efﬁcacy is still controversial
[151] and randomized clinical trials are needed to
clarify their effectiveness in these patients.
Beta-blockers (b-blockers) have been proposed in
patients with COVID-19 to antagonize the hyperinﬂammatory response [152,153], since beta2adrenergic receptors are expressed on several immune cells and their activation seems to promote
inﬂammatory activity and cytokines release
[154e157]. Therefore, targeting these receptors
could be beneﬁcial in counteracting the harmful
effects of the inﬂammatory hyperactivation that occurs in these patients. However, their potential
beneﬁcial effect in patients with COVID-19 needs to
be proven by randomized studies.

7. Conclusions
ACS may complicate the clinical course of
COVID-19. These patients usually present a particular clinical phenotype compared to non-COVID-19
patients, with higher thrombotic burden, presence
of multiple thrombotic lesions, poorer success of
revascularization procedures, and higher incidence
of non-obstructive CAD.
The pathophysiology of STEMI in SARS-CoV-2
positive patients is complex and includes hemostatic
abnormalities, excessive inﬂammatory response,
endothelial damage, and a mismatch between oxygen supply and demand. A deep knowledge of these
mechanisms may be crucial for the management of
these patients, and to plan a proper pharmacological
treatment. Antiplatelet agents, anticoagulants,
ACEIs, b-blockers, and statins may be helpful for
preventing ACS in patients with severe forms of
COVID-19, for reducing the risk of adverse events,
and improving the patients’ clinical outcome.
However, further evidence from randomized
studies is needed to substantiate their use in routine
clinical practice.
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